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Abstract
Most forms of chronic pain are inadequately treated by present therapeutic options. Compelling evidence has accumulated,
demonstrating that Nerve Growth Factor (NGF) is a key modulator of inflammatory and nociceptive responses, and is a
promising target for the treatment of human pathologies linked to chronic and inflammatory pain. There is therefore a
growing interest in the development of therapeutic molecules antagonising the NGF pathway and its nociceptor
sensitization actions, among which function-blocking anti-NGF antibodies are particularly relevant candidates. In this
respect, the rat anti-NGF aD11 monoclonal antibody (mAb) is a potent antagonist, able to effectively antagonize rodent and
human NGF in a variety of in vitro and in vivo systems. Here we show that mAb aD11 displays a significant analgesic effect in
two different models of persistent pain in mice, with a remarkable long-lasting activity. In order to advance aD11 mAb
towards its clinical application in man, anti-NGF aD11 mAb was humanized by applying a novel single cycle strategy based
on the a priori experimental determination of the crystal and molecular structure of the parental Fragment antigen-binding
(Fab). The humanized antibody (hum-aD11) was tested in vitro and in vivo, showing that the binding mode and the NGF
neutralizing biological activities of the parental antibody are fully preserved, with even a significant affinity improvement.
The results firmly establish hum-aD11 as a lead candidate for clinical applications in a therapeutic area with a severe unmet
medical need. More generally, the single-cycle structure-based humanization method represents a considerable
improvement over the standard humanization methods, which are intrinsically empirical and require several refinement
cycles.
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Introduction
The neurotrophin Nerve Growth Factor (NGF) [1] exerts a
wide range of physiological functions not only in the development
and maintenance of specific neuronal populations of the vertebrate
nervous system [2], [3], but also in some non neuronal cells,
including cells of the immune system such as mast cells, basophils
and monocytes [4]. It is worthy of note that, besides its broad
range of physiological effects, NGF is involved in several disease
states such as in certain chronic inflammatory or neuropathic pain
states [5], [6] and in several human malignancies [7].
There has been an increasing recognition that NGF regulates
the function of adult peripheral sensory neurons including small-
diameter nociceptive afferents, thereby exerting a pain modulation
activity through nociceptor sensitization [8]. Interestingly, NGF-
induced activation of the Tropomyosin-related receptor kinase A
(TrkA) receptor on mast cells as well as on macrophages and
monocytes recruited at an injured or inflamed site determines the
release of mediators that further contribute to the sensitization of
sensory nociceptors [6]. Therefore, NGF modulates pain responses
and changes pain thresholds by two principal mechanisms: a direct
TrkA-mediated activation of pain signaling through receptors and
channels on nerves such as Transient Receptor Potential cation
channel subfamily V member 1 (TRPV1) and TetrodoToXin
(TTX) insensitive voltage-gated sodium channel Nav, and
indirectly through the TrkA mediated degranulation of mast cells
and basophils.
Thus, the NGF-TrkA system appears to be a master control
system for pain, in spreading inflammation and increasing the
electrical neuronal response in nerve endings, functionally placed
upstream in the hierarchy of the pain regulation process.
Besides a large body of evidence in animal models, the clinical
relevance of the functional role of the NGF-TrkA system in pain
has received considerable and compelling validation in humans.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32212First of all, increased NGF levels are found in inflamed tissues and
fluids from patients with pathological conditions such as arthritis
[9], pancreatitis and prostatitis [10]. In humans, exogenous NGF
infusions either locally or systemically, induce pain [11]. Finally,
humans harboring mutations in the NGFB [12], [13] and TrkA
genes [14] suffer congenitally from a complete loss of pain
sensations, leading to severe self-mutilation.
For all these reasons, there has been a great interest in the
development of antagonists of NGF as analgesic drugs for chronic
and inflammatory pain conditions [15] such as osteoarthritis [16].
In this respect, antibodies against NGF constitute the strategy of
choice to antagonize the actions of NGF, ever since the pioneering
‘‘immunosympathectomy’’ experiments by Levi-Montalcini [1],
[17]. Indeed, the potent analgesic effects of anti-NGF antibodies
have been well documented in a variety of animal pain models [6].
The rat anti-NGF monoclonal antibody (mAb) aD11 [18]
deserves a special interest, as a therapeutic candidate, because it
binds mouse NGF (mNGF) with picomolar affinity [19] with no
cross-reactivity towards closely related members of the neurotro-
phin superfamily [20] and antagonizes very effectively its
biological function in a variety of in vitro and in vivo systems [21],
[22], [23], [24], [25].
In this study we demonstrate the potent and remarkably long
lasting analgesic activity of the mAb aD11 on different rodent
models of tonic/chronic pain. In order to pursue its therapeutic
development, mAb aD11 was humanized by a novel strategy,
exploiting the a priori 3D crystal structure determination of the
parental rat Fab aD11 (PDB_ID: 1ZAN) [26], [27]. This resulted
to be a crucial approach, that allowed to humanize aD11 antibody
variable regions, by Complementary Determining Regions
(CDRs) grafting, in a single cycle, obtaining a humanized version
(hum-aD11) whose binding characteristics and NGF antagonizing
activity, both in vitro and in vivo, are fully preserved with respect to
the parental rat counterpart.
Results
Mab aD11 binds human NGF equally well as mouse NGF
A basic requirement for mAb aD11 to be employed in human
clinical applications is that its binding affinity for hNGF should be
comparable to that for rodent NGF. The epitope recognized by
mAb aD11 was identified in Loops I and II of mNGF. While the
sequences of rat and human NGF in this region are identical, for
the mouse and human NGF they differ at position 40 (Figure 1A).
A structural alignment of Loop I and Loop II of the mouse and
human NGF crystallographic structures (PDB_ID: 1BTG,
PDB_ID: 1WWW) [28], [29] respectively, shows a good
superposition (Figure 1B).
Thus, we can reliably predict that mAb aD11 binds to hNGF
equally well as to mNGF. Indeed, an ELISA assay, with solid-
phase coated mNGF and hNGF and serial dilutions of mAb aD11,
confirms that mAb aD11 recognizes hNGF and mNGF with a
comparable affinity (Figure 1C). At the functional level, the
potency of mAb aD11 to neutralize the activity of NGF from
different species was ascertained by the TF-1 cell proliferation
assay [33] exhibiting a similar concentration-dependent inhibition
of cell proliferation for human, rat and mouse NGF, respectively
(data not shown).
In vivo analgesic properties of anti-NGF mAb aD11 on
formalin-induced pain and on neuropathic pain
The antagonistic properties of mAb aD11 are well established,
as this anti-NGF antibody is extremely effective at neutralizing the
biological actions of NGF in a wide variety of in vivo systems [20],
[21], [22], [23], [24], [25], thanks to its extremely high binding
affinity [19] and epitope specificity [20], [27]. In order to confirm
the therapeutic potential of the aD11 antibody, its analgesic
properties were assessed in vivo on two different models of tonic/
chronic pain in mice.
In the formalin-induced inflammatory pain model, formalin
injection resulted in the typical biphasic response with the highest
peak after 5 min and a second phase of licking that started 15 min
after the treatment. The mAb aD11 was administered, either as
IgG or Fab fragment format, 45 min before formalin injection and
showed a significant analgesic effect (Figure 2A) clearly specific
for the second phase (late inflammatory phase, i.e. 15–40 min) of
the pain response. The analgesic effect was superior for the mAb
aD11 in the Fab format, by halving the response of persistent pain,
as compared either to saline (p,0.01) or to control mAb treatment
(p.0.05) (Figure 2A). The strong analgesic potency of Fab aD11
in relation to that of the whole IgG counterpart, may be due to its
higher diffusion rate and hence greater tissue penetration and
bioavailability.
The analgesic potency of mAb aD11 was further evaluated in a
mouse model of neuropathic pain, the Chronic Constriction Injury
(CCI) of the sciatic nerve [34], following two treatment protocols,
a short and a long lasting protocol (see Materials & Methods). In
both protocols (Figure 2B and Figure 2C), mAb aD11 (Intra-
Peritoneal injected (I.P.)) exhibited a very significant analgesic
effect, as compared to mouse IgG mock. In a first set of
experiments (short protocol) (Figure 2B), four I.P. injections of
mAb aD11 (from day 3 to day 6 after ligation of the nerve) were
able to significantly reduce mechanical allodynia, starting from
day 4 after surgery. On this basis, a second set of experiments with
a longer observation period (long lasting protocol, observation up
to 31 days following sciatic nerve ligature), was performed. The
observation of animals undergoing long lasting protocol revealed a
quite unexpected temporal profile for the strong analgesic activity
induced by mAb aD11 (Figure 2C). Two phases can be
recognized in the analgesic action: the first one identifies a
pharmacological effect of mAb aD11 (an effect which declined in
parallel with the drop of the antibody concentration in circulating
blood, reaching a minimum analgesic effect around day 17, i.e. one
week after the end of the treatment). After the gradual decline of
the anti-allodynic effect, in the second phase (from day 21 to day
31) mAb aD11 again reduced neuropathic pain, displaying a long-
term analgesic effect of the anti-NGF antibody (Figure 2C). This
long lasting analgesic effect is likely to involve persistent changes in
gene expression in sensory neurons, demonstrating that aD11
antibody is not just as a potent analgesic, but also a long-term
disease-modifying drug.
Structure-based humanization design of anti-NGF mAb
aD11
In order to advance its development towards clinical evaluation
in patients, mAb aD11 was humanized by a novel structure-based
strategy, taking advantage of the available 3D crystal structure of
the rat Fab aD11 (PDB_ID: 1ZAN) [26], [27]. The structural
information gained from the rat Fab aD11 crystallographic
structure was exploited to optimize the selection of the acceptor
human antibody framework regions (FWRs), onto which the
CDRs of the donor murine anti-NGF mAb aD11 were grafted.
The acceptor human FWRs for mAb aD11 humanization were
selected by a novel approach [35], based on a comparison of both
the primary (% sequence homology/identity) and the tertiary
structures (degree of structural similarity based on the root mean
square deviations (r.m.s.d) calculated by taking into account the C
a
skeleton atoms) of the parental antibody with all the available
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32212Figure 1. In vitro binding affinity of the parental mAb aD11 towards hNGF and mNGF. (a) Sequence alignment of mNGF, hNGF and rat
NGF (Loop I and Loop II are colored in magenta and green, respectively). (b) Overall structure of NGF and structural comparisons [30], [31] of Loop I
(in magenta) and Loop II (in green) from mNGF (PDB_ID: 1BTG, cyan) [28] and hNGF (PDB_ID: 1WWW, green) [29]. This Figure was prepared with
PyMOL [32]. (c) ELISA assay with mNGF and hNGF coating (5 mg/ml) and serial dilutions of parental mAb aD11. The experiments were done in
duplicate.
doi:10.1371/journal.pone.0032212.g001
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antibodies. A cluster of candidate human FWRs acceptors was
identified, scored on the basis of the highest level of homology/
identity of the sequences present in the Protein Data Bank [36], for
which high resolution X-ray structural data (i.e. not lower than
2.5 A ˚) were available. The search was performed at first by
considering the overall antibody variable regions (i.e. the Fv
fragment) and then by narrowing down to the FWRs. The selected
crystallographic structures were superimposed to that of the
parental FvaD11, using the ‘‘superimpose’’ software [37], and the
r.m.s.d for each individual structural comparison were calculated,
considering only the C
a atoms at the correspondent positions, on
the respective backbones, closer than 2.0 A ˚. Therefore, the
selection of the optimal human FWRs acceptors for humanization
was configured as a three-variable problem, resulting in a 3D plot
that combined the information from the primary structure
comparison (% sequence homology/identity both at the level of
the Fv or only of the FWRs) and from the tertiary structure
alignment (the degree of structure similarity expressed in terms of
r.m.s.d. and by the % of C
a atoms employed in the r.m.s.d.
calculations).
As shown in Figure S1, the 3D distributions of the clusters
were mutually consistent for all of the combinations of the
variables taken into account. Moreover, by comparing the
distances (Figure 3) between the point of each of the selected
acceptors to the one having the coordinates corresponding to
100% sequence homology/identity both at the level of the variable
regions of the heavy (VH) and of the light (Vk) chains Fv or only of
the FWRs, 0.00 A ˚ r.m.s.d. and 100% of C
a atoms employed in the
r.m.s.d. calculations, i.e. the ideal human or humanized antibody,
it was straightforward to unequivocally identify the best FRWs
acceptor candidate among the human or humanized antibody of
choice, both at the levels of the primary and tertiary structures.
Thus, on the basis of the described method, the humanized
antibody (PBD_ID: 1JPS) [38] was chosen as acceptor FWRs in
the ensuing process of CDR grafting in the humanization of the
aD11 antibody. The similarity of their FWRs is displayed at the
level of their Fv region, both by sequence alignment (Figure 4)
and the 3D structural superimposition (Figure 5A).
In order to design the final humanized form of the aD11
antibody (hum-aD11), first the CDRs residues of the parental
mAb aD11 (underlined in Figure 4) were combined with the
Figure 2. In vivo analgesic activity of parental mAb aD11 in inflammatory and neuropathic pain models. (a) Analgesic effects of aD11
antibody administration on the late phase (15–40 min) in the course of the formalin test. Treatment consisted in saline (negative control) or antibody
injection (single doses: 12.5 mg of mock mouse mAb or two different molecular formats of aD11, i.e. mAb or Fab) performed (in the same paw as for
formalin) 45 min before formalin injection and testing. Statistical analysis was performed on each phase (ANOVA and Fisher’s Test for comparison of
each couple of groups). Each experimental group included at least 8 animals. (b) Analgesic effects of aD11 antibody in the short lasting protocol of
neuropathic pain model: mAb aD11 significantly increased the value of ipsilateral/contralateral index (ratio between the threshold forces measured
for the two hind paws, the one ipsilateral to surgery and the contralateral one. Mean value 6 s.e.), starting from day 4 to day 14, one week after the
last antibody injection. Control mice were injected with either mock mouse IgG, (1.4 mg/Kg) or saline solution (sal). ANOVA test for repeated
measures resulted in statistical significance for treatment (p,0.0001), time (p,0.0001) and the interaction between the two factors (treatment6time)
(p,0.0001). (c) Analgesic efficacy of mAb aD11 (one dose: 2 mg/kg) in the long lasting protocol of neuropathic pain model. MAb aD11 increased the
ipsilateral/contralateral index, starting either from day 5. The analgesic effect, which disappeared around days 17–19, increases again to reach a
plateau between day 27 and day 31, identifying a late phase in the action of mAb aD11 (long-term effect). ANOVA test for repeated measures
resulted in statistical significance for treatment (p,0.005), time (p,0.005) and the interaction between two factors (treatment6time) (p,0.005).
doi:10.1371/journal.pone.0032212.g002
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mutations were introduced, as follows: positions L46 and L87 were
mutated (to the rat mAb aD11 residue at this position) to preserve
the interface between VH and Vk, whilst the H71 position was
retro-mutated (ARR) to maintain the characteristics of the
Vernier zones [39], [40]. Subsequently, following the comparison
with the main consensus sequences of human immunoglobulins, a
Figure 3. Selection of acceptor human FWRs for mAb aD11
humanization. Deviations of parental Fab aD11 from each of the
selected human and humanized antibody, taking into account the
sequence alignment and structural comparison (calculated considering
both the overall sequence homology and identity percentage and the
percentage of sequence homology and identity restricted to FWRs).
doi:10.1371/journal.pone.0032212.g003
Figure 4. Primary structure comparison. Sequence alignment of Vk (A) and VH (B), respectively of parental Fab aD11 (PDB_ID: 1ZAN) [26], [27]
with the selected template for humanization (PDB_ID: 1JPS) [38] and hum-aD11, obtained by CDRs grafting (highlighted in yellow) on PDB_ID: 1JPS
[38] FWRs (highlighted in magenta) with the retro-mutations (highlighted in green) and the mutation (highlighted in cyan) . The six CDRs are
underlined and the residues belonging to the Vernier zones are colored in red. The residues numbering is according to Kabat [39].
doi:10.1371/journal.pone.0032212.g004
Figure 5. Tertiary structure comparison. Structural alignment
between the variable domains of parental Fab aD11 (PDB_ID. 1ZAN)
[26], [27] in magenta (a) with the selected FWRs acceptor 1JPS [38] (in
cyan) and (b) with the model of the resulting humanized antibody after
CDRs grafting (whose FWRs are depicted in cyan, while its CDRs are in
magenta); (c) Model of the hum-aD11 after CDR grafting and
mutagenesis in the chosen FWRs. The residues of human and animal
origin are highlighted in cyan and violet, respectively.
doi:10.1371/journal.pone.0032212.g005
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in this position was unusual both in the donor and in the acceptor
FWRs, being therefore substituted by a well conserved residue in
human antibodies. The resulting alignment of the Fv of hum-
aD11 to the donor (parental aD11) and acceptor (PDB_ID: 1JPS)
[38] sequences is presented in Figure 4.
The structural model of the designed hum-aD11 was then
refined by energy minimization using the program CNS [41]. In
Figure 5B, an overlay of the Fv region of the parental aD11 and
the model of the Fv region of the hum-aD11 is shown. The
resulting model of the Fab fragment of hum-aD11 and the
modeled Fv region being assembled in a composite immunoglob-
ulin are shown in Figure 5C.
Hum-aD11 shows an enhanced in vitro NGF binding
affinity
In order to obtain the hum-aD11 as an antibody protein in the
IgG1 format, for its functional evaluation and characterization,
DNA sequences encoding hum-aD11 VH and Vk were synthesized
using overlapping oligonucleotides (Table S1), genetically fused to
the human c1 heavy and the k light constant regions, respectively
(to reconstitute a human IgG1 antibody) and cloned in suitable
eukaryotic expression vectors [42] that were used to co-transfect
Chinese Hamster Ovary (CHO) mammalian cells.
ELISA assay was performed on CHO transfectant supernatants,
to evaluate the binding of IgG1 hum-aD11 binding to mNGF and
compare it to the parental mAb aD11, expressed in the chimeric
immunoglobulinIgG1format,IgG1chim-aD11(rataD11variable
regions fused to the c1 heavy and the k light constant regions,
respectively) [22]. The IgG1 chim-aD11 and the rat mAb aD11
were previously shown to have overlapping NGF binding curves
[22]. The chim-aD11 and hum-aD11 in the human IgG1 format
were transiently expressed in CHO cells, purified by Protein A-
Sepharose and quantified by immunoblot. After normalization,
serial dilutions were tested by ELISA (Figure 6A). The results show
that IgG1 hum-aD11 binds mNGF equally well as the IgG1 chim-
aD11(and the parental ratmAbaD11).Quite surprisingly, not only
the NGF binding of the hum-aD11 IgG1 was not reduced, but on
the contrary the binding affinity appeared to increase, in
comparison to the chimeric IgG1 aD11 and to the parental rat
mAb aD11 (Figure 6A). This might be the result of a more
favorable interaction at the variable/constant domains interface in
the two antibodies. Thus, the single-cycle humanization procedure
was sufficient to fully reconstitute the NGF binding strength of the
parental antibody, even showing some binding improvement.
To confirm the likely affinity improvement of the IgG1 hum-aD11
by kinetic and quantitative affinity measurements, Surface Plasmon
Resonance (SPR) studies were performed, to compare the NGF
binding kinetics with respect to the parental and humanized antibodies,
by exploiting two different configurations aimed to avoid any avidity
effect due to the use of the IgG1 format as an analyte. Details of the
parental and humanized aD11 antibodies binding curves to hNGF are
reported in Figure 6B and Figure 6C, respectively. The humanized
version of the antibody, indeed showed a significantly higher affinity for
hNGF with respect to the parental version, KDvalues of 28.964.1 pM
and 451645 pM, respectively (Table 1).
Hum-aD11 fully preserves the in vitro NGF antagonistic
activity and the in vivo analgesic properties of the
parental mAb aD11
To verify that the IgG1 hum-aD11 maintained the ability of the
parental one to inhibit NGF biological activity in vitro, two cellular
models were employed.
First, in an NGF-induced neurite outgrowth bioassay on rat PC-
12 cells [43] (Figure 7A to Figure 7D) both the parental mAb
and the IgG1 hum-aD11 exerted identical effects. Indeed, mNGF
treated PC-12 cells (Figure 7A), preincubated with either the
parental mAb or the IgG1 hum-aD11, failed to show any neurite
outgrowth (Figure 7B and Figure 7C), as in the absence of
mNGF (Figure 7D). In control experiments NGF-induced
differentiation occurs normally (Figure 7A), even if mNGF was
preincubated with a non relevant mAb or with the concentrated
untransfected CHO cell supernatants (data not shown). The
nuclear morphology of IgG1 hum-aD11 treated PC-12, stained
with 49,6-diamidino-2-phenylindole (DAPI), under the different
conditions of the assays, was normal (data not shown), underlining
that the failure of cells treated with mNGF and IgG1 hum-aD11
to differentiate was not due to a non-specific toxic effect, but
indeed to the neutralization of NGF binding and of the ensuing
differentiation.
The ability of the parental mAb aD11 and the IgG1 hum-aD11
to inhibit the activation of human TrkA receptor by mNGF was
compared in 3T3 TrkA cells (ectopically expressing human TrkA
receptor, but not expressing the neurotrophin p75
NTR receptor).
As shown by Western-blot analysis of TrkA phosphorylation at
residue Y490 (Figure 7E), no activation of human TrkA receptor
could be detected in the cells treated with mNGF preincubated
either with the parental mAb aD11 or the IgG1 hum-aD11, as
well as in the absence of mNGF. In the control experiments,
mNGF-induced human TrkA activation occurred normally, also
in the presence of a non relevant antibody.
At the functional level, the potency of the mAb hum-aD11 to
neutralize the activity of NGF from different species was also
ascertained by the TF-1 cell-based proliferation bioassay [33]. The
mAb hum-aD11 inhibits TF-1 cell proliferation with a similar
potency (IC50 value of ca. 30 ng/ml) in the presence of human, rat
and mouse NGF, respectively (data not shown).
Finally the analgesic activity of the hum-aD11 antibody was
tested in the formalin-induced inflammatory pain model in vivo.
Since previous experiments with the parental mAb aD11 showed
that analgesic effect was greater for mAb aD11 in the Fab than in
the whole IgG format (Figure 2B), these experiments were
performed with the Fab fragment of hum-aD11, expressed in the
periplasm of bacterial cells. As shown in Figure 8, Fab hum-
aD11, was able to reduce formalin-evoked pain both in the early
and in the late phase (p,0.05) of the formalin test, with a stronger
effect in the latter phase (which is related the inflammatory
component of pain). The Fab hum-aD11 determined an identical
analgesic response (halving of the pain response), at the same
doses, as the parental rat-aD11 Fab fragment, and therefore it
clearly retains the analgesic properties of the parental antibody.
Discussion
In this paper we describe the humanization of rat mAb aD11,
which potently antagonizes the activity of NGF, a target of great
clinical relevance for various pathological situations, including
presently untreatable forms of chronic and inflammatory pain [8],
[15]. The humanized form of aD11 recapitulates the remarkable
affinity (which is even improved) and neutralizing potency
properties of the parental mAb aD11, including its analgesic
properties in rodent models of inflammatory pain. The results
obtained unequivocally prospect hum-aD11 as a lead therapeutic
candidate for human pathologies where antagonizing systemic or
local NGF activity in the periphery would be of clinical benefit.
The structure-based humanization strategy of mAb aD11 was
performed by a novel method, which overcomes the well known
Humanization of an Analgesic Monoclonal Antibody
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32212Figure 6. Hum-aD11 preserves the in vitro binding properties of the parental mAb aD11. (a) ELISA assay with mNGF coating (5 mg/ml);
serial dilutions of parental mAb aD11, chimeric IgG1 aD11 and IgG1 hum-aD11, Protein A-Sepharose purified from transiently cotransfected CHO cells
supernatants. (b) Binding curves of a range of concentrations (0.29–37.5 nM) of hNGF to immobilized parental mAb aD11 (immobilization level
1280.0 RU). (c) Binding curves of a range of concentrations (0.39–25.0 nM) of Fab hum-aD11 to immobilized hNGF (immobilization level 100.3 RU).
doi:10.1371/journal.pone.0032212.g006
Table 1. SPR analysis.
ka (1/Ms) kd (1/s) KD (pM) KA (1/M)
rat aD11 2.21610
560.22610
5 9.98610
2560.07610
25 451645 2.21610
960.22610
9
hum-aD11 3.80610
560.50610
5 1.10610
2560.06610
25 28.964.1 3.40610
1060.50610
10
Summary of the derived kinetic and equilibrium binding constants of parental IgG aD11 and Fab hum-aD11 towards hNGF.
doi:10.1371/journal.pone.0032212.t001
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whereby the CDRs of the parental rodent mAb are grafted onto
human acceptor FWRs. The standard humanization procedure
requires a laborious and time-consuming iterative procedure, to
derive a humanized antibody with affinity and binding properties
comparable to those of the parental one [47], [48], [49], [50].
Thus, the choice of the acceptor FWRs represents the critical point
in the procedure of antibody humanization by CDRs grafting,
leading most often to a significant binding affinity loss of the
humanized antibody [51], [52], [53], due to distortions of the
CDRs conformations by the human acceptor FWRs. This requires
a trial and error iterative procedure, to correct structurally
distorting residues and to reconstitute the original binding
properties of the parental antibody. A universal combinatorial
library of antibody FWRs suitable for humanizing exogenous
antibodies by CDR-grafting, based on a bioinformatics approach,
has been recently proposed [54] to address these issues. Even if
computer modeling simulations and predictions can be employed
to improve the outcome of humanization [44], [46], [55], the
fidelity of antibody models to the experimental structures is rather
low, especially concerning the CDR H3 loops, which are more
variable in sequence, length and structure [56], [57], [58], [59]
and more flexible [58], [60], [61] than the other CDRs. Moreover,
the conformations of CDR H3 strongly depend on the
neighbouring structural environment [58], and in a significant
number of Fv crystal structures they are not even structurally
defined. Therefore, reliable modelling of the CDR H3 is still a real
challenge [62]. Moreover the overall conformation of antigen
binding site of antibodies further depends in a complex and
unpredictable manner on movements at the Vk/VH interface [63].
Thus, antibody humanization by CDRs grafting, as such, can, and
has proved to be, an unpredictably daunting and laborious task.
On the other hand, the alternative method of Fv humanization by
resurfacing, in which only solvent accessible residues of the non-
human donor antibody are considered for substitution by
homologous residues belonging to human FWRs regions [64],
[65], [66], results in the presence of a higher number of non-
human residues that might represent cryptic epitopes contributing
to an immunogenic response in patients.
To overcome these drawbacks, we developed a new structure-
based humanization strategy, to improve over traditional CDR
grafting method. In the approach described here, we exploited the
high resolution crystallographic structure of the Fab aD11
(PDB_ID: 1ZAN) [26], [27] in order to optimize the key step in
the selection and choice of the human FWRs acceptors. This
structure-based methodology allowed us to readily humanize the
aD11 antibody in a single cycle, obtaining an engineered version
whose binding and biological activity both in vitro and in vivo closely
recapitulate those of the parental version. It is worth noting that
the NGF binding affinity of the humanized hum-aD11 is not only
maintained, but surprisingly and unpredictably improved, by an
order of magnitude, over that of the parental antibody. The
molecular underpinnings for such an unexpected affinity improve-
ment will require a further structural investigation of the
humanized antibody itself. With many antibodies of therapeutic
Figure 7. Hum-aD11 retains the biological activity of the
parental mAb aD11 in vitro. (a–d) mNGF induced differentiation of
PC-12 cells. Neurite outgrowth inhibition assay: photomicrographs of
PC-12 cells, treated with (a) mNGF 100 ng/ml alone or preincubated (b)
with mAb aD11 (5 mg/ml) or (c) with IgG1 hum-aD11 (5 mg/ml),
concentrated from stable cotransfected CHO cells supernatants. (d)
Negative control: untreated PC-12 cells. (e) TrkA phosphorylation
inhibition assay in 3T3 TrkA cells. 3T3 TrkA cells were incubated with
the indicated combinations of mNGF, parental mAb aD11, IgG1 hum-
aD11 (purified by Protein A-Sepharose) and the irrelevant mAb SV5 as a
negative control. Cell lysates were separated on a 10% SDS gel and
phosphorylated TrkA detected using anti-phospho-Y490 TrkA Ab. The
ubiquitous band of tubulin served as gel loading control.
doi:10.1371/journal.pone.0032212.g007
Figure 8. Analgesic activity of the hum-aD11 in the formalin-
induced inflammatory pain model. Dose/Response effect of Fab
hum-aD11 on the early (0–15 min) and late phase (15–40 min) in the
course of the formalin test in CD1 mice. Treatment consisted in
antibody injection (Fab hum-aD11 vs mock IgG) performed (in the same
paw as for formalin) 45 min, before formalin injection and testing.
Statistical analysis was performed on each phase (ANOVA and Fisher’s
Test for comparison of each couple of groups).
doi:10.1371/journal.pone.0032212.g008
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need for their humanization for use in patients is mandatory. The
single-cycle structure-based method is a considerable improvement
over the standard humanization methods, which are intrinsically
empirical and require several trial and error refinement cycles.
The method described here may significantly accelerate the
clinical development path of many monoclonal antibodies of
therapeutical interest.
The second major conclusion of this study establishes the anti-
NGF hum-aD11 as an effective lead candidate for clinical
applications in a therapeutic area that represents a severe unmet
medical need. Pain is the most common symptom for which
patients seek medical assistance, and most forms of chronic and
inflammatory pain are inadequately treated by present therapeutic
options. Compelling evidence has accumulated, demonstrating
that the NGF-TrkA system is a key modulator of inflammatory
and nociceptive responses and a master control system for pain,
functionally placed upstream in the hierarchy of the pain
regulation process [6], [67]. There is, therefore, a strong rationale
for the development of a new generation of analgesic therapeutic
interventions, based on antagonising the NGF pathway via
inhibition of its interactions to receptors [8], [15]. In this respect
the large and rather flat ligand-receptor binding interfaces
disclosed by the crystal structures of the complexes between
NGF and its receptors p75
NTR and TrkA [29], [68], [69], make
the rational design of high affinity and specific small-molecule
antagonists of these interacting surfaces a daunting prospect.
Moreover, small molecule NGF-TrkA antagonists are more likely
than larger antibody molecules to cross the blood-brain barrier,
leading to unwanted neurological side effects. For these reasons
the use of function-blocking antibodies targeting the NGF ligand
[27], [70] or its TrkA receptor [71], [72], [73] represent one
obvious strategy to develop new pain therapeutics [8], [15].
The first antibody in this group reaching clinical evaluation in
humans is tanezumab, a humanized anti-NGF monoclonal
antibody [70], [74]. The therapeutic concept of blocking the
activity of NGF for chronic and inflammatory pain received a very
strong validation from the results of proof-of concept clinical trials
showing that tanezumab can very effectively and persistently
relieve joint pain and improve functions in moderate-to-severe
osteoarthritis patients [75]. However, in a subsequent Phase 3
clinical study of tanezumab for osteoarthritis of the hip and knee,
16 treated subjects showed joint failure and required total joint
replacement [16], [75]. This led the U.S Food and Drug
Administration to put on hold the clinical programs for
tanezumab, until more information on the incidence and causes
of these adverse events is gained (http://clinicaltrials.gov/ct2/
results?term=ngf+antibody). While these events could be ascribed
to causes to be determined, related to the NGF/TrkA system in
vivo, antibody-specific causes cannot be excluded and should be
considered. In this respect, comparative evaluations of different
anti-NGF antibodies will be very informative.
Although several mAbs were raised against NGF (reviewed in
[74]), the mAb aD11 deserves a special interest, not only because
of its picomolar affinity [19], antagonistic potency and specificity,
but also because its NGF neutralizing properties have been very
extensively verified in a diverse set of in vivo situations [20], [21],
[22], [23], [24], [25] and because it is the only anti-NGF
monoclonal antibody for which a 3D structure has been derived
[26], [27]. We now further show that the anti-NGF mAb aD11
displays very significant NGF antagonistic properties in relevant
murine pain models, with a remarkable and surprising long-lasting
analgesic property that may be of high clinical relevance. Although
the mechanistic dissection of this long-term analgesic effect remain
to be further characterized, it appears to be directly related to
NGF-TrkA signaling in adult nociceptor neurons, since a similar
long-lasting persistent analgesic effect was observed after admin-
istration of the neutralizing anti-TrkA MNAC13 antibody [73].
Thus, interrupting the activation of NGF-TrkA signaling in
chronic and inflammatory pain states might induce a therapeu-
tically beneficial feedback loop, prospecting anti-NGF ad anti-
TrkA antibodies as analgesics with disease-modifying properties.
These results establish hum-aD11, the humanized counterpart
of mAb aD11, as a lead candidate with a strong therapeutic
potential not only in the pain arena, but for all those pathological
states where an excess of NGF expression and/or activity is
detrimental.
Materials and Methods
Construction and cloning of the cDNAs of the variable
regions of hum-aD11
cDNAs of hum-aD11 VH and Vk were obtained by gene
synthesis using overlapping oligonucleotides (Table S1) according
to Kolbinger et al. [76]. After overlap assembly PCR, fragments of
the correct size were purified from agarose gel and directionally
cloned in expression vectors for IgG1 expression [42], respectively
BssHII/BstEII in VH Express vector for hum-aD11 VH and
ApaLI/BglII in Vk Express vector for hum-aD11Vk.
In order to produce Fab hum-aD11 in the bacterial periplasm,
the following two expression cassettes were cloned to express hum-
aD11 VH and hum-aD11 Vk in fusion with human constant
regions of the heavy (hCH) and the light (hCk) chains. In details,
hum-aD11 Vk was directionally cloned (NcoI/HindIII) in frame
with hCk (HindIII/NotI) in pET22b (Novagen) to obtain hum-
aD11 light chain in pET22b. After inserting the PelB secretion
sequence (NdeI/NcoI) in pET28 (Novagen), hum-aD11 VH was
directionally cloned (NcoI/NheI) in frame with hCH (NheI/XhoI) and
with C-terminal his-tag to obtain hum-aD11 heavy chain in
pET28_ PelB.
At each cloning step, positive clones, isolated by PCR screening
directly on bacterial colonies, were confirmed by DNA sequenc-
ing.
Expression of hum-aD11 in the IgG1 and Fab formats
The CHO cells (The European Collection of Cell Cultures,
Sigma-Aldrich, Product nu 85050302), grown in 90mm dishes,
were transfected with 3 mg IgG1 hum-aD11 expression plasmids
(1.5 mg of hum-aD11 VH in VH Express and 1.5 mg of hum-aD11
Vk in Vk Express) and with 3 mg chimeric aD11 expression
plasmids (1.5 mg of rat aD11VH in VH Express and 1.5 mg of rat
aD11 Vk in Vk Express) [22], using FuGENE (Roche) according
to the manufacturer’s protocols. Conditioned medium was
collected 72 hrs after transfection.
To select double transfectant clones expressing IgG1 hum-
aD11, CHO cells were cotransfected as reported above, using the
same amount of EcoRI linearized plasmids. 36 hrs after transfec-
tion, micophenolic acid (50 mg/ml) and G418 (500 mg/ml) were
added. Conditioned media were concentrated to 0.2 ml final
volume using Microcon concentrators (Millipore) or purified using
Protein A-Sepharose (GE Healthcare).
Protein concentrations were estimated by immunoblot. In
details 5 ml of each purified sample or concentrated conditioned
medium were spotted on a nitrocellulose membrane. After
blocking with PBS (5% non fat dry milk), the membrane was
incubated at first with an anti-human polyclonal antibody (Pierce)
diluted 1:500 in PBS (5% non fat dry milk), acting as primary Ab,
followed by the anti-goat Ab, coupled to horseradish peroxidase
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conjugates were detected with the electrochemiluminescence
protocol developed by Amersham Corp.
The amounts of human IgG in the different samples were
normalized after densitometric scanning and standards of purified
human IgG (Sigma) were used to determine absolute protein
levels; as negative control for concentrated conditioned media,
concentrated CHO supernatant of untransfected cells was used.
In order to express hum-aD11 Fab, hum-aD11 heavy chain in
pET28_PelB and hum-aD11 light chain in pET22b were co-
transformed in BL21(DE3) E.coli cells. Cells were grown at 30uC
in M9CA broth supplied with kanamycin (50 mg/ml) and
ampicillin (100 mg/ml), induced at an OD600 nm of 0.9 by adding
0.5 mM IPTG and left to grow for 15 hrs. The cell pellet
resuspended in buffer A (50 mM Na phosphate pH 8, 0.5 M
NaCl, 5 mM MgCl2, 10 mM imidazole, 5% glycerol) was
incubated with 1 mM PMSF, 100 mg/ml lysozyme and 5 mg/ml
Dnase I, for 30 min and then sonicated on ice. Soluble extract was
loaded on Ni-NTA Superflow resin (Qiagen) equilibrated with
buffer A and Fab hum-aD11 was subsequently eluted with
250 mM imidazole. The collected fractions were then pooled and
loaded on a HiLoad 16/60 Superdex 75 (GE Healthcare) pre-
equilibrated with 20 mM Tris-HCl pH 8.5, 0.2 M NaCl, 5 mM
MgCl2, 5% glycerol. The fractions corresponding to the Fab hum-
aD11 were concentrated using an Amicon Ultra-15 centrifugal
filter unit (Millipore) with a membrane cut-off of 10 kDa.
ELISA assays
ELISA assays were performed according to Covaceuszach et al.
[72] with the following modifications.
In order to compare mAb aD11 binding towards human and
mouse NGF, mNGF (Alomone) and hNGF obtained according to
Covaceuszach et al. [77], were coated; followed by first serial
dilutions of mAb aD11 (1:2 dilutions in the concentration range
between 20 mg/ml and 18 ng/ml), acting as primary antibody,
and finally by the anti-rat antibody peroxidase conjugated (Dako)
acting as secondary antibody.
ELISA assay to compare chimeric and IgG1 hum-aD11
binding towards mNGF (Alomone) was performed with the
following modifications: serial dilutions of chimeric and IgG1
hum-aD11 were incubated and the anti-human polyclonal
antibody (Pierce) was used as primary antibody and the anti-goat
antibody peroxidase conjugated as secondary antibody (Dako). All
the experiments were done in duplicate.
Surface Plasmon Resonance
SPR measurements were performed with a BIACore instrument
(BIACore AB, Uppsala, Sweden) in triplicate.
Parental rat mAb aD11 was immobilized on three CM5 sensor
chips by cross-linking the amine groups according to the
manufacturer’s instructions, obtaining SPR signals, after comple-
tion of the chip regeneration cycles, respectively of 1025, 1040 and
1280 resonance units (RU). The binding kinetics for rat mAb
aD11 were determined by injection on each surface of serial
dilutions (in the 0.29 nM to 37.5 nM concentration range) of
hNGF in PBS buffer with addition of 0.005% v/v Surfactant P20
at a flow rate of 30 ml/min.
The binding kinetics for Fab hum-aD11 were determined by
immobilizing hNGF on three CM5 sensor chips by cross-linking
the amine groups according to the manufacturer’s instructions,
obtaining SPR signals, after completion of the chip regeneration
cycle, respectively of 89, 93 and 100 resonance units. Serial
dilutions (in the 0.39 nM to 25 nM concentration range) of Fab
hum-aD11 (kindly provided by PanGenetics UK Ltd.) in HBSEP
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.005%
Surfactant P20, pH 7.4) containing 100 mg/ml bovine serum
albumin, were injected on each surface at a flow rate of 50 ml/min.
Data were analyzed using the BIAevaluation 3.0 package (GE
Healthcare) to yield the apparent equilibrium constant KD
(defined as the ka/kd ratio) and KA (defined as the kd/ka ratio).
NGF bioassay with PC-12 cells
Rat adrenal gland phaeochromocytoma PC-12 cells (Sigma-
Aldrich, Product nu 88022401) [43] were maintained in RPMI
1640 medium (Life Technologies, Milano, Italy), supplemented
with 10% fetal calf serum. PC-12 cells were primed with 50 ng/ml
mNGF (Alomone) on collagen-coated (type I, BD Biosciences)
35 mm Petri dishes at a density of 0,25610
5 cells per dish for the
second day after seeding onward. Priming was carried out for 5–6
days, with mNGF added every 3 days, then cells were detached
and plated on collagen-coated 35 mm Petri dishes. For differen-
tiation assays, cells were incubated with 100 ng/ml mNGF for 2–4
days in the presence or absence of parental mAb or IgG1 hum-
aD11 (5 mg/ml; 1 hour preincubation).
TrkA Phosphorylation-Inhibition Assay
TrkA Phosphorylation-Inhibition Assay was performed accord-
ing to Ugolini et al. [73], with the following modification. Prior
treatment, 100 ng/ml mNGF was preincubated in the presence or
absence of parental mAb aD11, IgG1 hum-aD11 or irrelevant
mAb SV5 (2.5 mg/ml) in serum-free medium supplemented with
0.05% BSA for 1 hour.
BALB/C 3T3-transfected cells (3T3-TrkA), mouse embryonic
fibroblast cell line stable transfected with human TrkA full-length,
were kindly provided by Dr. Stefano Alema ` [Consiglio Nazionale
delle Ricerche, Istituto di Biologia Cellulare e Neurobiologia, Via
E. Ramarini 32, I-00015 Monterotondo Scalo (Roma), Italy].
The human premyeloid cell line TF-1 was purchased from the
American Type Culture Collection (ATCC, Product nu CRL-
2003).
Inflammatory and neuropathic pain models
Formalin test and neuropathic pain tests were performed
according to Ugolini et al. [73].
In particular, regarding the neuropathic pain model, the CCI of
the sciatic nerve [34] was performed following two treatment
protocols, i.e. Protocol A (short lasting): 4 I.P. administrations at
days 3, 4, 5, 6 after surgery of mAb aD11 (single dose: 50 mg/
injection, roughly equivalent to 1.4 mg/Kg) and Protocol B (long
lasting): 8 I.P. administrations at days 3, 4, 5, 6, 7, 8, 9, 10 after
surgery of mAb aD11 (single dose: 70 mg/injection, roughly
equivalent to 2 mg/Kg).
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Supporting Information
Figure S1 Primary and tertiary structural comparison.
3D structural and sequence comparisons between the crystal
structure of the Fab rat aD11 and the crystal structures of human
or humanized antibodies, Fabs, IgGs or of their complexes with
Humanization of an Analgesic Monoclonal Antibody
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e32212antigens indentified in the PDB database (release #101, July
2002). The plotted variables are: The skeleton C
a r.m.s.d , the %
of C
a atoms considered in the r.m.s.d calculations and A) % of
sequence homology on both the variable domains B) % of
sequence identity on both the variable domains C) % of sequence
homology on the FWRs D) % of sequence identity on the FWRs.
(TIF)
Table S1 Oligonucleotides sequences used in the syn-
thesis of the CDRs grafted hum-aD11 Vk (A) and VH (B)
regions by overlap-assembly PCR.
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